Triest: Estrone + Estradiol + Estriol: The Definitive Guide

What is Triest?

Triest is a compounded estrogen mixture containing estrone, estradiol and estriol in varying amounts. The National Academies distinguishes this three-estrogen mixture from Biest’s two-estrogen mixture. Neither name defines a universally standardized medicine, ratio, route or concentration. The actual pharmacy preparation determines what is administered. [2]

The mixture’s hormone names may be bioidentical, meaning molecularly identical to naturally occurring hormones. That description does not certify a pharmacy batch, prove a physiological tissue pattern or make an extra estrogen component necessary. Approved medicines can also contain bioidentical hormones; preparation method and molecular identity are different questions. [1], [4]

Compounded Triest is not FDA-approved as a finished drug. FDA also states there is no approved US estriol-containing medicine. Legitimate patient-specific compounding needs remain possible, but they should be explained rather than presented as universal personalization or an approved all-country protocol. This guide does not certify local stock or foreign authorization. [1], [3], [4]

What must be known before the preparation is used?

This row is a prescription-identification framework, not a dose recommendation. Obtain each ingredient, amount per unit, amount actually administered, route, vehicle, application site, dispenser and calendar. If the label only names a ratio, ask how that ratio maps to actual amounts and whether the component order is explicit. No commonly mentioned ratio is endorsed as optimal here. [1], [2], [3]

The fact that three hormones occur naturally does not establish the body’s relevant postmenopausal concentrations or a superior external mixture. Absorption and metabolism differ by form and route. A change in pharmacy, vehicle or concentration needs a new review even if the familiar Triest name stays on the label. [1], [2]

Evidence note: no standardized Triest start, escalation or conversion is verified. Actual product directions and evidence remain formulation-specific.

Which symptoms and claims should be separated?

A person may seek treatment for sweats, hot flashes, sleep interrupted by sweats or local vaginal discomfort. Those are distinct goals, with regulated product choices and their own evidence. A custom three-estrogen mixture does not inherit every benefit of estrogen therapy or every result of estriol alone. [1], [4], [6]

Claims that estrone supplies missing balance, estriol blocks cancer or Triest broadly improves immunity, brain health or metabolism require formulation-specific clinical evidence. Such superiority is not verified in the primary sources checked. Discuss the concrete symptom and a practical measure of improvement; more ingredients do not themselves make the treatment more appropriate. [1], [2], [4]

Why can one route not stand in for another?

Capsules, creams and troches can expose a person differently. The National Academies describes multi-ingredient preparation stability and bioavailability as questions requiring appropriate evidence. A swallowed mixture, sublingual preparation and skin cream should not be recorded simply as the same estrogen dose. [1], [2]

Use only the site and route actually prescribed. A skin preparation is not automatically suitable inside the vagina or on the face. Ask the pharmacist about administration, contact transfer, cleaning and a missed dose for the exact vehicle. Route-specific evidence from licensed estradiol products cannot silently validate every custom Triest form. [1], [2], [3]

How much direct Triest evidence is established?

The full ACOG consensus and National Academies chapter describe limited high-quality evidence for custom compounded menopausal hormone therapy and emphasize formulation complexity. They do not establish an optimal Triest ratio or a long-term advantage over approved estradiol regimens. That is an evidence gap, not proof that every person’s reported relief is false. [1], [2]

A study of estriol alone, a Biest exposure study or a broad observational compounded-hormone cohort does not automatically test this exact three-estrogen preparation. Separate the finished formula, comparator, population, duration and outcome before using a paper to justify a clinical claim. A serum value is not a trial of endometrial protection or cancer risk. [1], [2], [5]

Adding ingredients also adds compatibility and stability questions. If formal preparation-specific data are unavailable, say so and compare a well-characterized option for the actual symptom. The guide does not turn absence of a large direct trial into a claim that no research anywhere exists. [1], [2]

Does the third estrogen change uterine or systemic safety?

All three named ingredients are estrogens. They do not replace a progestogen where systemic estrogen requires endometrial protection. BMS identifies unreliable protection from transdermal micronized progesterone; listing progesterone cream alongside Triest does not certify adequate opposition. Dose, route and exposure days of the protection plan must be explicit. [2], [5]

FDA does not support a safer-estriol claim. Ordinary estrogen eligibility concerns such as unexplained bleeding, relevant cancer, thrombosis/vascular disease and liver disease still need clinical review. Compounding additionally raises potency, contamination and labeling risks; that is distinct from assuming every pharmacy batch is defective. [1], [3], [4]

Sudden chest pain, breathlessness, swollen painful leg or neurologic symptoms requires urgent assessment. New or persistent bleeding deserves evaluation even if a mixture was marketed as gentle. A lack of case reports or warning text cannot establish a zero-risk product. [3], [4], [6]

What should follow-up verify beyond a hormone number?

Review the complete formula, consistency of use, changes in the dispensing device, other hormones, symptom response and bleeding. ACOG does not recommend adjunct hormone tests to set compounded menopausal doses; salivary testing should not be presented as a validated way to recreate a personal youthful hormone ratio. Tests for a separate clinical question remain possible. [1]

NICE suggests review at three months then annually, sooner for difficulties. Persistent unscheduled systemic-HRT bleeding beyond six months from starting or three months after changing treatment needs prompt assessment; concerning symptoms can need earlier care. The review should also decide whether the reason for compounding still applies and whether a regulated alternative now meets the need. [1], [6]

How should a different estrogen regimen be introduced?

A switch starts with identifying the actual prior ingredients and amounts. There is no verified conversion from total Triest milligrams or ratio to an estradiol patch. Define the new product, route, calendar and adequate uterine protection before replacing only one part of the regimen. NICE allows gradual reduction or immediate stopping but does not supply a custom Triest taper. [1], [5], [6]

Plan for symptom recurrence, review and separate vaginal or bone goals. If other hormones are included in the same preparation, changing it also changes those exposures. A serious suspected reaction needs prompt assessment; a routine change can address preference, tolerability, access or evidence with a clear written plan. [1], [3], [6]

What storage and expiry information is required?

The compounder must provide conditions and a beyond-use date for the actual preparation. No universal Triest temperature, refrigeration requirement or shelf life is verified. An approved capsule’s expiry or a different cream’s rule cannot establish stability for this multi-ingredient formula. [2], [3]

Keep packaging and the ingredient/concentration label for review. Ask what to do after heat, moisture, damage or a change in texture and whether the device still measures the intended application. A familiar name on a container is insufficient when the route or batch cannot be identified. [2], [3]

What changes when choosing a regulated alternative?

Approved bioidentical estradiol and progesterone products offer specified amounts, manufacturing and product evidence. That does not guarantee no adverse effects, but it provides information absent from a custom mixture. A clinician can select a systemic or local route based on the actual symptom and an adequate protection plan. [1], [4], [6]

If a genuine allergy or unavailable form requires compounding, explain that need and the safeguards. Adding estrone to Biest does not itself create a more complete or safer regimen. Compare the complete preparation, not the number of estrogens or the naturalness of their names. [1], [2], [3]

What can the archived public discussion support?

The legacy collection links a public r/Menopause thread about compounded bioidentical therapy, not a verified Triest-only product cohort. A fresh full-thread retrieval on October 2 failed. The older archive’s broad themes were perceived relief, provider recommendations, cost and disagreement about compounded versus approved medicines; these are archival context, not refreshed current sentiment. [7]

No identities, quotes, engagement counts, scores, submitted doses or response times are reproduced. It would be misleading to isolate a Triest effect when other hormones and products were used. The remaining useful questions are why the formula was chosen, what the actual label contains and whether a safer-characterized complete regimen would meet the same goal. [1], [2], [7]

Common questions about Triest

Do three natural estrogens recreate a proven normal balance?

No physiological or outcome guarantee follows from the name. The formulation and clinical evidence must be assessed. [1], [2] The presence of estrone, estradiol and estriol does not show that the finished mixture reproduces physiological exposure or improves outcomes over a suitable approved treatment. Amount, route, vehicle and metabolism still matter. Ask which clinical need the actual formulation is intended to meet and what evidence supports that choice. See the evidence boundaries. [1], [2]

Is there a validated universal ratio or starting dose?

No such regimen is established in the primary sources checked. Use only the actual prescribed preparation. [1], [2] A ratio cannot substitute for the amount of each ingredient, concentration, dispensed quantity and application instructions. Those details may vary between pharmacies or refills carrying the same name. Keep the prescription and container together and have changes explained before use. See the preparation checklist rather than borrowing another person’s formula. [1], [2]

Does estriol supply uterine protection?

No. It is estrogen, and systemic use with a uterus still needs adequate opposition. [4], [5] A third estrogen does not supply a progestogen’s endometrial role. The full systemic regimen and any added products need review, and a skin progesterone preparation is not a reliable substitute for established protection. Report new bleeding rather than assume the mixture’s natural description makes it harmless. See risks and uterine protection. [4], [5]

Are community accounts current Triest evidence?

No. The legacy public thread is broad compounded therapy and freshly unavailable; no current product-specific sentiment is claimed. [7] The access limitation prevents the archive from supporting a refreshed account of current experiences or a product-specific effect. Broad concerns about customization, trust or symptoms can help frame questions, but cannot validate a formulation or dose. Use the community section for those qualified themes and the clinical sources for treatment decisions. [7]

Can a Triest ratio be converted directly into a patch dose?

No validated universal conversion was found in the primary sources checked. A ratio expresses relative ingredients, not their delivered exposure, and changing route introduces another important difference. A switch should identify the actual preparation, treatment goal and complete uterine-protection plan where needed, with follow-up based on the new regimen. Do not create a replacement dose from the ratio alone. See the comparison for why compounded mixtures and manufactured estradiol products remain separate formulations. [1], [2], [5]

Glossary

Definitions for interpreting the product, calendar and limitations.

Estrogen

A hormone class that includes estradiol, estrone and estriol.

MHT / HRT

Menopausal hormone therapy; hormone replacement therapy is a broader term.

Vasomotor symptoms

Menopausal hot flashes and night sweats.

GSM

Genitourinary syndrome of menopause: symptoms and tissue changes involving genital and urinary areas.

Systemic treatment

Medicine delivered through the circulation to act throughout the body.

Local treatment

Treatment directed mainly at the tissue where it is applied; some absorption can still occur.

First-pass metabolism

Initial liver processing after a swallowed medicine is absorbed from the gut.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excess growth of uterine lining; some forms can precede cancer.

Progestogen

A medicine class including progesterone and synthetic progestins, used for uterine protection in systemic HRT.

Micronized progesterone

Progesterone processed into small particles to support absorption; route and schedule remain important.

Continuous combined

Estrogen and progestogen taken without planned monthly breaks.

Sequential

Progestogen taken during a defined part of an estrogen-treatment cycle.

Withdrawal bleed

A planned bleed associated with stopping the progestogen part of a sequential regimen.

Hysterectomy

Surgery to remove the uterus; it does not always remove the ovaries.

VTE

Venous thromboembolism: a clot in a vein, including leg clots and pulmonary embolism.

Pulmonary embolism

A clot blocking an artery in the lungs; a medical emergency.

Absolute risk

How often an event occurs in a specified population over a specified time.

Relative risk

An event rate in one group compared with another; it needs baseline risk to show practical size.

Contraindication

A circumstance in which a medicine should not be used according to its label.

Compounded product

A pharmacy-prepared medicine; approval of an ingredient does not approve the finished preparation.

Estrone / E1

One of the estrogens in Triest; it is not a progestogen.

Estradiol / E2

An estrogen found in approved products and compounded mixtures.

Estriol / E3

Another estrogen; no FDA-approved estriol medicine in the US.

Bioidentical

Molecular identity with a naturally occurring hormone, not a quality certification.

Vehicle

The cream or other base carrying ingredients and influencing delivery.

Mixture ratio

Relative ingredient amounts; incomplete without named order, concentration and administered quantity.

Beyond-use date

Pharmacy-defined usable limit for the actual compounded preparation.

Pharmacokinetics / PK

How exposure changes with absorption, distribution, metabolism and elimination.

How was this guide researched?

Regulatory and clinical sources define compounding evidence limits. The actual prescription and pharmacy determine the mixture’s ingredients, route and instructions. Marketing records do not prove stock; guidelines inform care without changing authorization. Public accounts remain separate from clinical evidence. Sources identify document revision and access.

How this page was made

This Doserly editorial guide was prepared with AI assistance using public sources checked October 2, 2026. No independent clinician reviewer is claimed. Doserly develops a commercial tracking app. Original figures explain concepts and do not represent trial results. The directory identifies source revisions and access limitations. January 2027 is a review target; new evidence can require an earlier check.

Sources and updates

Related guides